Breaking News, Financial News

Financial Report: Enzon 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Enzon 3Q Revenues: $49 million (+4%) 3Q Loss: $2.0 million (earnings were $87.5 million in 3Q07) Comments: Total product sales were $28.9 million in the quarter (+16%) driven by Oncaspar sales, up 19% to $12.5 million. Contract manufacturing revenues were $5.3 million (+40%) due to growth from additional business and timing of shipments to customers. Royalty revenues were $14.6 million (-20%) as a result of the sold portion of Peg-Intron royalties. R&D expenses increased to $15.7 mi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters